Why Carasent stock moves
Carasent fell slightly, in line with the market.
Written after the close on ·
Why today
16,292 news analyzed todayCarasent fell slightly, in line with the market.
No company news explains the move in the last session.
Over the last five trading days Carasent fell sharply, while the wider market was roughly flat.
The session was an ordinary day for Carasent, within its usual daily range.
The most recent company news came on 16 October, a Redeye research update, which is background only.
Today's move of −0.97% was 1.0 times a normal day's 0.9%. OMX Stockholm 30 moved −1.01% on the same day.
Carasent −0.97%OMX Stockholm 30 −1.01%In step with the market
What analysts expect, and how often they have been right
Analysts’ estimates for Carasent.
Carasent earned more than expected in 2 out of 8 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 2 out of 7 reports with a measured move, against about 63% of reports from Nordic companies.
Price targets
Latest price 25.60 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 0.18 SEK. For the current fiscal year, expected earnings per share changed from 0.63 SEK three months ago to 0.62 SEK now. 2026 estimate: 0.62 SEK. 2027 estimate: 1.01 SEK. One analyst made the yearly estimates. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. August 27: Buy about 916 thousand SEK. August 26: Buy about 603 thousand SEK. May 28: Sell about 232 thousand SEK. May 28: Buy about 472 thousand SEK. February 17: Buy about 230 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 3 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +24% and earnings per share went from -0.58 SEK to 0.50 SEK.
Revenue, profit and market cap
RevenueProfitMarket capbn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 3 out of 3 years.Market cap (Now): 1.7 bn SEKRevenue 2025: 344 m SEK
What the key figures say about Carasent
The figures connect what Carasent earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -0.60 SEK–0.50 SEK. Peers: NordHealth -2.32 NOK, Aiforia Technologies -0.42 EUR, Physitrack -3.93 SEK. 2026 estimate: 0.62 SEK (0.62 SEK–0.62 SEK). 2027 estimate: 1.01 SEK (1.01 SEK–1.01 SEK).
What the company sold during the year.
2022–2025: 208 m SEK–344 m SEK. Peers: NordHealth 53.1 m EUR, Aiforia Technologies 2.9 m EUR, Physitrack 14.3 m EUR.
The percentage of revenue left after the costs of running the business.
2022–2025: −18.0%–2.7%. Peers: NordHealth −28.4%, Aiforia Technologies −316.4%, Physitrack 6.8%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −4.9%–4.3%. Peers: NordHealth −25.8%, Aiforia Technologies −77.5%, Physitrack −40.2%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 39.9–54.9. 2026 estimate: 41.3. 2027 estimate: 25.3.
What investors pay for each unit the company sells.
2022–2025: 3.33–6.35. Peers: Aiforia Technologies 11.30.
Money paid to shareholders per share, summed by calendar year.
2017–2025: 0.00 SEK–1.92 SEK.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.0%–17.0%. Peers: NordHealth 0.0%, Aiforia Technologies 0.0%, Physitrack 0.0%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -108.57–-1.10. Peers: Physitrack 0.77.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 0.87–2.33. Peers: Aiforia Technologies 1.97.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 16.6–54.5.
Cash left after investments, divided by the number of shares.
2022–2025: -1.02 SEK–-0.01 SEK. Peers: NordHealth -0.09 EUR, Aiforia Technologies -0.38 EUR, Physitrack 0.03 EUR.
The percentage of assets financed by shareholders’ equity.
2022–2025: 83.3%–89.5%.
What followed similar falls?
Including reinvested dividends, Carasent fell 4.8% over the latest five trading days. Since November 7, 2016, falls at least this large were followed by a higher value 21 trading days later in 13 out of 34 non-overlapping periods. The median was −2.3%, against +0.0% for an ordinary 21-day period, which ended higher 30 times in 100.
Such a fall has not said much about the next month.
−2.3% · 13/34
More about Carasent
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Johan Kallblad, board memberBuyabout 916 thousand SEK
- Johan Kallblad, board memberBuyabout 603 thousand SEK
- Johan Kallblad, board memberSellabout 232 thousand SEK
- Johan Kallblad, board memberBuyabout 472 thousand SEK
- Henric Carlsson, board memberBuyabout 230 thousand SEK
Earnings report
On its last 13 report days Carasent usually moved about 4.6%. On a normal day it moves 0.9%.
+4.58% +7.25% −4.97% +1.74%
10,000 SEK in Carasent bought on October 20, 2020 is worth 11,600 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 20,900 SEK.
What would 10,000 SEK in Carasent be worth today? →
What would 10,000 SEK in Carasent be worth today?
11,600 SEK
with dividends reinvested, bought on October 20, 2020. The same amount in OMX Stockholm 30 with dividends would have become 20,900 SEK.
At worst it was worth 4,600 SEK (December 14, 2023).
The five biggest days of the journey
· +29.3%
· +28.3% · the whole market fell 0.1% the same day · report day
· +20.7%
· +20.3%
· −19.8%
Earlier days
−4.83% market −0.11% Carasent fell sharply over the past week's trading days. Read →
Carasent fell sharply over the past week's trading days.
Carasent has had no company news in the past two weeks.
Healthcare peers on Nasdaq Stockholm were roughly flat to slightly up, which points to no sector-wide selling.
The likely drivers are general investor repositioning or thin news flow rather than a identifiable event.
−1.69% market +0.83% Carasent fell, while OMX Stockholm 30 rose clearly. Read →
Carasent fell, while OMX Stockholm 30 rose clearly.
Carasent moved against the market.
No company news explains the drop.
Over the last five trading days, Carasent fell clearly while the market rose slightly.
Earlier news, a nomination committee for the 2027 general meeting and a research update, is background only.
+0.95% market −0.08% Carasent rose slightly, without company news. Read →
Carasent rose slightly, without company news.
Carasent rose, an ordinary move for the stock while the market stayed flat.
Over the last five trading days, Carasent fell slightly while the OMX Stockholm 30 rose slightly, so it lagged the market.
No company news explains the session's move; Carasent has had no company news in the past two weeks.
The wider Healthcare sector gained modestly over the same days, which may have lent some support.
−1.67% market +0.48% Carasent fell clearly, moving against the market. Read →
Carasent fell clearly, moving against the market.
No company news explains it.
Over the last five trading days, Carasent edged down slightly while OMX Stockholm 30 rose clearly.
Trading was well below its usual level, so the move may reflect thin demand rather than new information.
Earlier news about the nomination committee is background only.
+1.70% market −0.29% Carasent rose, against a slightly weaker OMX Stockholm 30. Read →
Carasent rose, against a slightly weaker OMX Stockholm 30.
No company news explains the move.
Over the last five trading days, Carasent was roughly unchanged while the market rose clearly, so it lagged.
Trading was well below its usual level, so the move may partly reflect thin trading.
−0.37% market +3.01% Carasent was roughly flat over the week, while the OMX Stockholm 30 index rose clearly, so it lagged the market. Read →
Carasent was roughly flat over the week, while the OMX Stockholm 30 index rose clearly, so it lagged the market.
Carasent has had no company news in the past two weeks.
Trading was well below its usual level, so the price moved on few trades.
The last session saw a clear rise against a slightly weaker market.
−1.86% market +0.41% Carasent fell clearly, without company news. Read →
Carasent fell clearly, without company news.
No company news in the last session explains the drop.
Over the last five trading days Carasent fell slightly, while the market rose sharply.
Trading volume was about twice a normal session, so the move was active.
Earlier news, a board nomination committee announcement and a CFO comment on AI investments, is background rather than the cause.
−0.19% market +1.57% Carasent was roughly unchanged, while OMX Stockholm 30 rose clearly. Read →
Carasent was roughly unchanged, while OMX Stockholm 30 rose clearly.
No company news explains the move.
Over the last five trading days it fell slightly, in line with the market.
Trading volume was well above its usual level, but the move was an ordinary one for Carasent.
−4.76% market −3.67% Carasent fell sharply over the last five trading days, moving in line with the broader Stockholm market, which also dropped sharply. Read →
Carasent fell sharply over the last five trading days, moving in line with the broader Stockholm market, which also dropped sharply.
The move was ordinary for the stock, and trading was well above its usual level.
Company news was mostly positive: the Q3 report showed sales up strongly and higher operating profit.
Market and sector selling likely weighed on the shares.
−5.27% market −2.51% Carasent fell very sharply without a clear company news trigger. Read →
Carasent fell very sharply without a clear company news trigger.
Carasent fell far more than OMX Stockholm 30, which fell sharply, so the drop was stock-specific.
The last five trading days also saw a sharp fall, roughly twice a normal five-day move.
Trading volume was about three times normal, so heavy selling likely drove it.
Carasent's latest quarterly report came out last week, with sales up 32%, which earlier supported the stock.
+4.21% market +0.17% Carasent rose very sharply, with no company news explaining it. Read →
Carasent rose very sharply, with no company news explaining it.
Over the same day OMX Stockholm 30 was roughly flat, so Carasent moved on its own.
The move was about four times a normal day for the stock, and trading was well above its usual level.
Over the last five trading days Carasent rose clearly while the wider market slipped slightly.
The strong third-quarter report, with sales up 32%, came out last week and is the likely backdrop for the rally.
−3.70% market −0.89% {'text': "Carasent fell very sharply, moving far more than the market, which also fell clearly. Read →
{'text': "Carasent fell very sharply, moving far more than the market, which also fell clearly.
Over the last five trading days the stock rose slightly while OMX Stockholm 30 was roughly flat.
The move looks like a broad sell-off, and trading volume was well above normal, so heavy selling is likely.
Earlier, Carasent's third-quarter report beat expectations on sales, with revenue up 32 percent.
Learn more · Why do stocks go up and down?